Comparison
Wegovy vs Zepbound
Wegovy (semaglutide) and Zepbound (tirzepatide) are the two most-prescribed GLP-1 weight loss injections in the US. Both are FDA-approved for chronic weight management, but they work slightly differently and produce different average results.
| Category | Wegovy | Zepbound | Winner |
|---|---|---|---|
| Drug class | GLP-1 receptor agonist | GLP-1 + GIP receptor agonist | Zepbound |
| Average weight loss (68 weeks) | 15% of body weight | 18-21% of body weight | Zepbound |
| FDA approved for weight loss | Yes (2021) | Yes (2023) | Wegovy |
| Insurance coverage | Wider coverage | Growing but narrower | Wegovy |
| Common side effects | Nausea, diarrhea, constipation | Nausea, diarrhea, injection site reactions | Wegovy |
| Track record | Longer real-world data | Newer but strong trials | Wegovy |
| Starting dose | 0.25 mg weekly | 2.5 mg weekly | Tie |
| Best for | Patients with broad insurance coverage | Patients wanting maximum weight loss | Tie |
Final verdict
Zepbound shows slightly stronger average weight loss in clinical trials, but Wegovy has a longer track record and wider insurance coverage. The best choice depends on your insurance formulary, tolerance for side effects, and what your doctor recommends.